Loading...

King, Christopher R

Title(s)Professor of Clinical _____, Radiation Oncology
Phone310-825-9771
vCardDownload vCard
    Other Positions
    Title(s)Professor of Clinical _____, Urology


    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Pan X, Levin-Epstein R, Huang J, Ruan D, King CR, Kishan AU, Steinberg ML, Qi XS. Dosimetric predictors of patient-reported toxicity after prostate stereotactic body radiotherapy: Analysis of full range of the dose-volume histogram using ensemble machine learning. Radiother Oncol. 2020 Apr 17; 148:181-188. PMID: 32388444.
      View in: PubMed
    2. Levin-Epstein R, Qiao-Guan G, Juarez JE, Shen Z, Steinberg ML, Ruan D, Valle L, Nickols NG, Kupelian PA, King CR, Cao M, Kishan AU. Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer. Front Oncol. 2020; 10:539. PMID: 32373529.
      View in: PubMed
    3. King CR, Fritz BA, Escallier K, Ju YS, Lin N, McKinnon S, Avidan MS, Palanca BJ. Association Between Preoperative Obstructive Sleep Apnea and Preoperative Positive Airway Pressure With Postoperative Intensive Care Unit Delirium. JAMA Netw Open. 2020 Apr 01; 3(4):e203125. PMID: 32310284.
      View in: PubMed
    4. Singhrao K, Ruan D, Fu J, Gao Y, Chee G, Yang Y, King C, Hu P, Kishan AU, Lewis JH. Quantification of fiducial marker visibility for MRI-only prostate radiotherapy simulation. Phys Med Biol. 2020 Feb 05; 65(3):035015. PMID: 31881546.
      View in: PubMed
    5. Kishan AU, Chu FI, King CR, Seiferheld W, Spratt DE, Tran P, Wang X, Pugh SE, Sandler KA, Bolla M, Maingon P, De Reijke T, Nickols NG, Rettig M, Drakaki A, Liu ST, Reiter RE, Chang AJ, Feng FY, Sajed D, Nguyen PL, Kupelian PA, Steinberg ML, Boutros PC, Elashoff D, Collette L, Sandler HM. Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. Eur Urol. 2020 Feb; 77(2):201-208. PMID: 31718822.
      View in: PubMed
    6. Jiang NY, Dang AT, Yuan Y, Chu FI, Shabsovich D, King CR, Collins SP, Aghdam N, Suy S, Mantz CA, Miszczyk L, Napieralska A, Namysl-Kaletka A, Bagshaw H, Prionas N, Buyyounouski MK, Jackson WC, Spratt DE, Nickols NG, Steinberg ML, Kupelian PA, Kishan AU. Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019 11 01; 105(3):628-636. PMID: 31276777.
      View in: PubMed
    7. Yuan Y, Aghdam N, King CR, Fuller DB, Weng J, Chu FI, Mardirossian G, Patel A, Nickols NG, Kupelian PA, Steinberg ML, Collins SP, Kishan AU. Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):149-154. PMID: 31108142.
      View in: PubMed
    8. Wang C, Kishan AU, Yu JB, Raldow A, King CR, Iwamoto KS, Chu FI, Steinberg ML, Kupelian PA. Association between Long-Term Second Malignancy Risk and Radiation: A Comprehensive Analysis of the Entire Surveillance, Epidemiology, and End Results Database (1973-2014). Adv Radiat Oncol. 2019 Oct-Dec; 4(4):738-747. PMID: 31673667.
      View in: PubMed
    9. Lubin DJ, Holden SB, Rettig MB, Reiter RE, King CR, Lee JM, Wallace DW, Calais J. Prostate Cancer Pulmonary Metastasis Presenting as a Ground-Glass Pulmonary Nodule on 68Ga-PSMA-11 PET/CT. Clin Nucl Med. 2019 05; 44(5):e353-e356. PMID: 30789399.
      View in: PubMed
    10. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. Eur Urol. 2020 Jan; 77(1):3-10. PMID: 30992160.
      View in: PubMed
    11. Kishan AU, Tyran M, Weng J, Upadhyaya S, Lamb J, Steinberg M, King C, Cao M. Stereotactic body radiotherapy to the prostate and pelvic lymph nodes: A detailed dosimetric analysis of a phase II prospective trial. Br J Radiol. 2019 Jul; 92(1099):20181001. PMID: 30912957.
      View in: PubMed
    12. Wang C, Raldow AC, Nickols NG, Nguyen PL, Spratt DE, Dess RT, Yu JB, King CR, Chu FI, Chamie K, Litwin MS, Saigal CS, Reiter RE, Liu ST, Rettig MB, Chang AJ, Steinberg ML, Kupelian PA, Kishan AU. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. Eur Urol Oncol. 2019 Feb 01. PMID: 31411981.
      View in: PubMed
    13. Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N, Buyyounouski MK, Spratt DE, Linson PW, Hong RL, Nickols NG, Steinberg ML, Kupelian PA, King CR. Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Netw Open. 2019 02 01; 2(2):e188006. PMID: 30735235.
      View in: PubMed
    14. Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, Kupelian PA, Steinberg ML, King CR. Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis. JAMA Oncol. 2019 01 01; 5(1):91-96. PMID: 30326032.
      View in: PubMed
    15. Kishan AU, Cook RR, King CR. Reply to Marieke J. Krimphove, Junaid Nabi, Alexander P. Cole, and Quoc-Dien Trinh's Letter to the Editor re: Ronald D. Ennis, Liangyuan Hu, Shannon N. Ryemon, Joyce Lin, Madhu Mazumdar. Brachytherapy-based Radiotherapy and Radical Prostatectomy Are Associated with Similar Survival in High-risk Localized Prostate Cancer. J Clin Oncol 2018;36:1192-8: Setting the Standard: The Importance of Defining the Standard of Care for Comparative Effectiveness Analyses. Eur Urol Oncol. 2019 Mar; 2(2):224-225. PMID: 31017101.
      View in: PubMed
    16. Shaverdian N, Kishan AU, Veruttipong D, Demanes DJ, Kupelian P, McCloskey S, Steinberg ML, King CR. Impact of the Primary Information Source Used for Decision Making on Treatment Perceptions and Regret in Prostate Cancer. Am J Clin Oncol. 2018 09; 41(9):898-904. PMID: 28537990.
      View in: PubMed
    17. Kang JJ, Reiter RE, Steinberg ML, King CR. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. Eur Urol Oncol. 2018 10; 1(5):378-385. PMID: 31158076.
      View in: PubMed
    18. Kishan AU, Duchesne G, Wang PC, Rwigema JM, Kishan AU, Saigal C, Rettig M, Steinberg ML, King CR. Discord Among Radiation Oncologists and Urologists in the Postoperative Management of High-Risk Prostate Cancer. Am J Clin Oncol. 2018 08; 41(8):739-746. PMID: 28301348.
      View in: PubMed
    19. Kishan AU, Cook RR, King CR. Optimal Treatment for High-Risk Prostate Cancer-Reply. JAMA. 2018 07 24; 320(4):405. PMID: 30043055.
      View in: PubMed
    20. Kishan AU, Duchesne G, Wang PC, Rwigema JM, Saigal C, Rettig M, Steinberg ML, King CR. Does Specialty Bias Trump Evidence in the Management of High-risk Prostate Cancer? Am J Clin Oncol. 2018 06; 41(6):549-557. PMID: 27560157.
      View in: PubMed
    21. Hegde JV, Collins SP, Fuller DB, King CR, Demanes DJ, Wang PC, Kupelian PA, Steinberg ML, Kamrava M. A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy. Am J Clin Oncol. 2018 05; 41(5):502-507. PMID: 27322703.
      View in: PubMed
    22. Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG. Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. J Nucl Med. 2018 11; 59(11):1714-1721. PMID: 29653978.
      View in: PubMed
    23. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. Int J Radiat Oncol Biol Phys. 2018 07 15; 101(4):883-888. PMID: 29976500.
      View in: PubMed
    24. Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA. 2018 03 06; 319(9):896-905. PMID: 29509865.
      View in: PubMed
    25. King C, Sherwin JC, Ratnarajan G, Salmon JF. Twenty-year outcomes in patients with newly diagnosed glaucoma: mortality and visual function. Br J Ophthalmol. 2018 12; 102(12):1663-1666. PMID: 29502068.
      View in: PubMed
    26. Kang JJ, Steinberg ML, Kupelian P, Alexander S, King CR. Whole Versus Partial Bladder Radiation: Use of an Image-guided Hypofractionated IMRT Bladder-preservation Protocol. Am J Clin Oncol. 2018 Feb; 41(2):107-114. PMID: 26535994.
      View in: PubMed
    27. Kang JJ, Reiter RE, Kummer N, DeKernion J, Steinberg ML, King CR. Wrong to be Right: Margin Laterality is an Independent Predictor of Biochemical Failure After Radical Prostatectomy. Am J Clin Oncol. 2018 Jan; 41(1):1-5. PMID: 26237192.
      View in: PubMed
    28. Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. J Nucl Med. 2018 02; 59(2):230-237. PMID: 29123013.
      View in: PubMed
    29. Kishan AU, Cheng EM, Schmidt E, Saigal C, Reiter RE, Kupelian PA, Steinberg ML, King CR. Use of the Electronic Medical Record to Facilitate Intervention for Patients With Rising Prostate-Specific Antigen Values After Radical Prostatectomy: A Feasibility Study. JCO Clin Cancer Inform. 2017 11; 1:1-6. PMID: 30657383.
      View in: PubMed
    30. Hegde JV, Demanes DJ, Veruttipong D, Raince J, Park SJ, Raman SS, Nickols NG, King CR, Kishan AU, Steinberg ML, Kamrava M. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy. Brachytherapy. 2017 Nov - Dec; 16(6):1106-1112. PMID: 28807747.
      View in: PubMed
    31. Hegde JV, Veruttipong D, Said JW, Reiter RE, Steinberg ML, King CR, Kishan AU. Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer. Urology. 2017 Sep; 107:171-177. PMID: 28552819.
      View in: PubMed
    32. Shaverdian N, Steinberg ML, King CR. In Reply to Scott. Int J Radiat Oncol Biol Phys. 2017 05 01; 98(1):217. PMID: 28586966.
      View in: PubMed
    33. Wang C, Kishan AU, Kamrava M, Steinberg ML, King CR. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study. Int J Radiat Oncol Biol Phys. 2017 08 01; 98(5):1045-1052. PMID: 28721887.
      View in: PubMed
    34. Walling AM, Beron PJ, Kaprealian T, Kupelian PA, Wenger NS, McCloskey SA, King CR, Steinberg M. Considerations for Quality Improvement in Radiation Oncology Therapy for Patients with Uncomplicated Painful Bone Metastases. J Palliat Med. 2017 Feb 23. PMID: 28437208.
      View in: PubMed
    35. Kishan AU, King CR. Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer. Semin Radiat Oncol. 2017 07; 27(3):268-278. PMID: 28577834.
      View in: PubMed
    36. Sandler KA, Shaverdian N, Cook RR, Kishan AU, King CR, Yang I, Steinberg ML, Lee P. Treatment trends for patients with brain metastases: Does practice reflect the data? Cancer. 2017 Jun 15; 123(12):2274-2282. PMID: 28178376.
      View in: PubMed
    37. Wang C, King CR, Kamrava M, Iwamoto KS, Chen AM, Low D, Kupelian PA, Steinberg ML. Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer. Radiother Oncol. 2017 04; 123(1):133-138. PMID: 28187996.
      View in: PubMed
    38. Kishan AU, Steinberg ML, Kupelian PA, King CR. Reply to Thomas Van den Broeck, R. Jeffrey Karnes, and Steven Joniau's Letter to the Editor re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol 2017;71:766-73. Eur Urol. 2017 11; 72(5):e123-e124. PMID: 28111115.
      View in: PubMed
    39. Kishan AU, Kupelian PA, Steinberg ML, King CR. Urinary toxicity after stereotactic body radiotherapy: The boy who cried wolf? Cancer. 2017 02 01; 123(3):531-532. PMID: 27997685.
      View in: PubMed
    40. Shaverdian N, Verruttipong D, Wang PC, Kishan AU, Demanes DJ, McCloskey S, Kupelian P, Steinberg ML, King CR. Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):516-525. PMID: 28126301.
      View in: PubMed
    41. Johnson SB, Soulos PR, Shafman TD, Mantz CA, Dosoretz AP, Ross R, Finkelstein SE, Collins SP, Suy S, Brower JV, Ritter MA, King CR, Kupelian PA, Horwitz EM, Pollack A, Abramowitz MC, Hallman MA, Faria S, Gross CP, Yu JB. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol. 2016 11; 121(2):294-298. PMID: 27890426.
      View in: PubMed
    42. King CR. The dose-response of salvage radiotherapy following radical prostatectomy: A systematic review and meta-analysis. Radiother Oncol. 2016 11; 121(2):199-203. PMID: 27863963.
      View in: PubMed
    43. Qi XS, Wang JP, Gomez CL, Shao W, Xu X, King C, Low DA, Steinberg M, Kupelian P. Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy. Radiother Oncol. 2016 10; 121(1):113-117. PMID: 27587270.
      View in: PubMed
    44. Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol. 2017 05; 71(5):766-773. PMID: 27452951.
      View in: PubMed
    45. Edel A, King CR. Re: Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?: L. J. Sokoll, Z. Zhang, D. W. Chan, A. C. Reese, T. J. Bivalacqua, A. W. Partin and P. C. Walsh J Urol 2016;195:330-336. J Urol. 2016 07; 196(1):283-4. PMID: 27048826.
      View in: PubMed
    46. Kishan AU, Steinberg ML, Kupelian PA, King CR. In Regard to Bauman et al. Int J Radiat Oncol Biol Phys. 2015 Dec 01; 93(5):1162-3. PMID: 26581152.
      View in: PubMed
    47. Kishan AU, Wang PC, Upadhyaya SK, Hauswald H, Demanes DJ, Nickols NG, Kamrava M, Sadeghi A, Kupelian PA, Steinberg ML, Prionas ND, Buyyounouski MK, King CR. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. Pract Radiat Oncol. 2016 Jul-Aug; 6(4):268-75. PMID: 26850649.
      View in: PubMed
    48. Laviana AA, Ilg AM, Veruttipong D, Tan HJ, Burke MA, Niedzwiecki DR, Kupelian PA, King CR, Steinberg ML, Kundavaram CR, Kamrava M, Kaplan AL, Moriarity AK, Hsu W, Margolis DJ, Hu JC, Saigal CS. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer. Cancer. 2016 Feb 01; 122(3):447-55. PMID: 26524087.
      View in: PubMed
    49. King CR, Kamrava M, Wang PC, Steinberg ML. In Regard to Mariados et al. Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):936-7. PMID: 26530767.
      View in: PubMed
    50. Kishan AU, Park SJ, King CR, Roberts K, Kupelian PA, Steinberg ML, Kamrava M. Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy. Br J Radiol. 2015; 88(1056):20150658. PMID: 26463234.
      View in: PubMed
    51. Kishan AU, Lamb JM, Jani SS, Kang JJ, Steinberg ML, King CR. Pelvic nodal dosing with registration to the prostate: implications for high-risk prostate cancer patients receiving stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2015 Mar 15; 91(4):832-9. PMID: 25752398.
      View in: PubMed
    52. Gomez CL, Xu X, Qi XS, Wang PC, Kupelian P, Steinberg M, King CR. Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2015 Jul-Aug; 5(4):257-62. PMID: 25749214.
      View in: PubMed
    53. Kang JJ, Reiter RE, Steinberg ML, King CR. Ultrasensitive prostate specific antigen after prostatectomy reliably identifies patients requiring postoperative radiotherapy. J Urol. 2015 May; 193(5):1532-8. PMID: 25463990.
      View in: PubMed
    54. Rwigema JC, King C, Wang PC, Kamrava M, Kupelian P, Steinberg ML, Lee P. Stereotactic body radiation therapy for abdominal and pelvic oligometastases: Dosimetric targets for safe and effective local control. Pract Radiat Oncol. 2015 May-Jun; 5(3):e183-91. PMID: 25413386.
      View in: PubMed
    55. King CR, Steinberg MS, Kupelian P. Perils of comparing toxicities between stereotactic body radiation and intensity-modulated radiation therapy for prostate cancer on the basis of incomplete demographic registries. J Clin Oncol. 2014 Oct 20; 32(30):3453. PMID: 25185084.
      View in: PubMed
    56. Dong P, Nguyen D, Ruan D, King C, Long T, Romeijn E, Low DA, Kupelian P, Steinberg M, Yang Y, Sheng K. Feasibility of prostate robotic radiation therapy on conventional C-arm linacs. Pract Radiat Oncol. 2014 Jul-Aug; 4(4):254-60. PMID: 25012834.
      View in: PubMed
    57. King CR, Collins S, Fuller D, Wang PC, Kupelian P, Steinberg M, Katz A. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys. 2013 Dec 01; 87(5):939-45. PMID: 24119836.
      View in: PubMed
    58. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, Meier R, Wang J, Kupelian P, Steinberg M, Katz A. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013 Nov; 109(2):217-21. PMID: 24060175.
      View in: PubMed
    59. King CR. Adjuvant versus salvage radiotherapy for high-risk prostate cancer patients. Semin Radiat Oncol. 2013 Jul; 23(3):215-21. PMID: 23763888.
      View in: PubMed
    60. King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):104-11. PMID: 22795730.
      View in: PubMed
    61. Nagarajan R, Margolis D, Raman S, Sarma MK, Sheng K, King CR, Verma G, Sayre J, Reiter RE, Thomas MA. MR spectroscopic imaging and diffusion-weighted imaging of prostate cancer with Gleason scores. J Magn Reson Imaging. 2012 Sep; 36(3):697-703. PMID: 22581787.
      View in: PubMed
    62. King CR. Adjuvant versus salvage radiotherapy after prostatectomy: the apple versus the orange. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):1045-6. PMID: 22284027.
      View in: PubMed
    63. Nagarajan R, Margolis D, Raman S, Sheng K, King C, Reiter R, Thomas MA. Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer. Adv Urol. 2012; 2012:374805. PMID: 22216026.
      View in: PubMed
    64. Mehta N, King CR, Agazaryan N, Steinberg M, Hua A, Lee P. Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: A pooled analysis of biological equivalent dose and local control. Pract Radiat Oncol. 2012 Oct-Dec; 2(4):288-295. PMID: 24674167.
      View in: PubMed
    65. King C. Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial. Front Radiat Ther Oncol. 2011; 43:428-437. PMID: 21625167.
      View in: PubMed
    66. Grant JD, Litwin MS, Kwan L, Lee SP, Steinberg ML, King CR. Does hormone therapy exacerbate the adverse effects of radiotherapy in men with prostate cancer? A quality of life study. J Urol. 2011 May; 185(5):1674-80. PMID: 21419449.
      View in: PubMed
    67. King CR, Brooks JD, Gill H, Presti JC. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Feb 01; 82(2):877-82. PMID: 21300474.
      View in: PubMed
    68. King CR. Adjuvant radiotherapy after prostatectomy: does waiting for a detectable prostate-specific antigen level make sense? Int J Radiat Oncol Biol Phys. 2011 May 01; 80(1):1-3. PMID: 21277112.
      View in: PubMed
    69. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol. 2011 Jan 10; 6:3. PMID: 21219625.
      View in: PubMed
    70. Wiegner EA, King CR. Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2010 Oct 01; 78(2):442-8. PMID: 20137864.
      View in: PubMed
    71. King CR, Kapp DS. To treat pelvic nodes or not: could the greater testicular scatter dose from whole pelvic fields confound results of prostate cancer trials? J Clin Oncol. 2009 Dec 20; 27(36):6076-8. PMID: 19858377.
      View in: PubMed
    72. Fowler J, King CR. Don't squeeze hypofractionated schedules into too-short overall times. Int J Radiat Oncol Biol Phys. 2009 Oct 01; 75(2):323-5. PMID: 19735858.
      View in: PubMed
    73. Mao W, Hsu A, Riaz N, Lee L, Wiersma R, Luxton G, King C, Xing L, Solberg T. Image-guided radiotherapy in near real time with intensity-modulated radiotherapy megavoltage treatment beam imaging. Int J Radiat Oncol Biol Phys. 2009 Oct 01; 75(2):603-10. PMID: 19735886.
      View in: PubMed
    74. King CR, Maxim PG, Hsu A, Kapp DS. Incidental testicular irradiation from prostate IMRT: it all adds up. Int J Radiat Oncol Biol Phys. 2010 Jun 01; 77(2):484-9. PMID: 19733013.
      View in: PubMed
    75. King CR, Lo A, Kapp DS. Testicular dose from prostate cyberknife: a cautionary note. Int J Radiat Oncol Biol Phys. 2009 Feb 01; 73(2):636-7; author reply 637. PMID: 19147028.
      View in: PubMed
    76. Lu SX, Alpdogan O, Lin J, Balderas R, Campos-Gonzalez R, Wang X, Gao GJ, Suh D, King C, Chow M, Smith OM, Hubbard VM, Bautista JL, Cabrera-Perez J, Zakrzewski JL, Kochman AA, Chow A, Altan-Bonnet G, van den Brink MR. STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease. Blood. 2008 Dec 15; 112(13):5254-8. PMID: 18838616.
      View in: PubMed
    77. King CR, Ferrari M, Brooks JD. Prognostic significance of prostate cancer originating from the transition zone. Urol Oncol. 2009 Nov-Dec; 27(6):592-7. PMID: 18799332.
      View in: PubMed
    78. Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Sep 01; 72(1):236-46. PMID: 18722274.
      View in: PubMed
    79. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009 Mar 15; 73(4):1043-8. PMID: 18755555.
      View in: PubMed
    80. King CR, Spiotto MT, Kapp DS. Obesity and risk of biochemical failure for patients receiving salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2009 Mar 15; 73(4):1017-22. PMID: 18707829.
      View in: PubMed
    81. Tran PT, Hara W, Su Z, Lin HJ, Bendapudi PK, Norton J, Teng N, King CR, Kapp DS. Intraoperative radiation therapy for locally advanced and recurrent soft-tissue sarcomas in adults. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):1146-53. PMID: 18394818.
      View in: PubMed
    82. King CR, Kapp DS. Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys. 2008 Jun 01; 71(2):346-50. PMID: 18234451.
      View in: PubMed
    83. King CR, Spiotto MT. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):23-7. PMID: 18207668.
      View in: PubMed
    84. Luxton G, Keall PJ, King CR. A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD). Phys Med Biol. 2008 Jan 07; 53(1):23-36. PMID: 18182685.
      View in: PubMed
    85. King CR, Presti JC, Brooks JD, Gill H, Spiotto MT. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2008 Apr 01; 70(5):1472-7. PMID: 17935902.
      View in: PubMed
    86. King CR, Freedland SJ, Terris MK, Kane CJ, Amling CL, Aronson WJ, Presti JC. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database. Urology. 2007 May; 69(5):921-6. PMID: 17482935.
      View in: PubMed
    87. Hsu A, Pawlicki T, Luxton G, Hara W, King CR. A study of image-guided intensity-modulated radiotherapy with fiducials for localized prostate cancer including pelvic lymph nodes. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):898-902. PMID: 17459610.
      View in: PubMed
    88. Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys. 2007 Sep 01; 69(1):54-61. PMID: 17459606.
      View in: PubMed
    89. King CR, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, Presti JC. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. Urology. 2007 Apr; 69(4):732-7. PMID: 17445660.
      View in: PubMed
    90. Pawlicki T, Kim GY, Hsu A, Cotrutz C, Boyer AL, Xing L, King CR, Luxton G. Investigation of linac-based image-guided hypofractionated prostate radiotherapy. Med Dosim. 2007; 32(2):71-9. PMID: 17472885.
      View in: PubMed
    91. Pawlicki T, Cotrutz C, King C. Prostate cancer therapy with stereotactic body radiation therapy. Front Radiat Ther Oncol. 2007; 40:395-406. PMID: 17641522.
      View in: PubMed
    92. King CR, McNeal JE, Gill H, Brooks JD, Srinivas S, Presti JC. Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade. Urology. 2006 Jun; 67(6):1229-34. PMID: 16765184.
      View in: PubMed
    93. Patel DA, Presti JC, McNeal JE, Gill H, Brooks JD, King CR. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol. 2005 Sep 01; 23(25):6157-62. PMID: 16135482.
      View in: PubMed
    94. King CR, Patel DA, Terris MK. Prostate biopsy volume indices do not predict for significant Gleason upgrading. Am J Clin Oncol. 2005 Apr; 28(2):125-9. PMID: 15803004.
      View in: PubMed
    95. King CR, Presti JC, Gill H, Brooks J, Hancock SL. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes? Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):341-7. PMID: 15145146.
      View in: PubMed
    96. King CR, McNeal JE, Gill H, Presti JC. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):386-91. PMID: 15145152.
      View in: PubMed
    97. King CR, Lehmann J, Adler JR, Hai J. CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat. 2003 Feb; 2(1):25-30. PMID: 12625751.
      View in: PubMed
    98. King CR, Fowler JF. Yes, the alpha/beta ratio for prostate cancer is low or "methinks the lady doth protest too much...about a low alpha/beta that is". Int J Radiat Oncol Biol Phys. 2002 Oct 01; 54(2):626-7; author reply 627-8. PMID: 12243843.
      View in: PubMed
    99. King CR. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models. Brachytherapy. 2002; 1(4):219-26. PMID: 15062170.
      View in: PubMed